The PARADIGMS randomized phase 3 trial compared fingolimod with intramuscular interferon beta-1a in children and adolescents aged 10 to under 18 years with multiple sclerosis. Fingolimod produced a substantially lower annualized relapse rate and fewer new or newly enlarged T2 lesions. Benefits were also observed in treatment-naive and younger subgroups. The findings are clinically important because childhood-onset MS can be highly inflammatory, and recurrent relapses may contribute to disability and cognitive burden during a vulnerable developmental period. The study provides evidence that a high-efficacy oral disease-modifying therapy can control pediatric MS more effectively than interferon. For HCPs, treatment selection still needs to account for infection risk, vaccination, adherence, monitoring requirements and the child's developmental context. Fingolimod also carries specific cardiac and ophthalmic precautions. The broader lesson is that paediatric MS should not automatically be treated as a milder version of adult disease; early disease control can be important for preserving neurological and developmental function. This directly complements IANCON's emphasis on precision and future-oriented MS care.